Navigation Links
Actos Lawsuit – Status Conference Convened in Federal Actos Bladder Cancer Multidistrict Litigation, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) July 27, 2013

Actos lawsuit claims continue to move forward in the U.S. District Court, Western District of Louisiana, where hundreds of Actos bladder cancer claims have been consolidated for pretrial proceedings, Bernstein Liebhard LLP reports. According to court documents, a Status Conference was convened on July 25th, 2013, at which time discovery and bellwether trial updates were among the issues discussed. The Court also scheduled the litigation’s next Status Conference for August 22, 2013. (In re: Actos Product Liability Litigation, MDL No. 2299)

“Our Firm has heard from numerous Actos users concerned that their long-term use of Actos caused their bladder cancer. We are pleased to see this litigation moving forward, and look forward to the commencement of bellwether trials early next year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to patients who developed bladder cancer after using the medication for an extended period of time.

Actos Lawsuits
Actos is approved to lower blood sugar in patients with type 2 diabetes. In June 2011, the U.S. Food & Drug Administration (FDA) warned that use of Actos for more than one year had been associated with an increased risk of bladder cancer.* That same month, regulators in several European countries pulled Actos from the market because of its association with bladder cancer. **

Since then, more than 2,400 Actos bladder cancer claims have been filed in the multidistrict litigation underway in Louisiana, all of which allege long-term use of Actos may cause or worsen bladder cancer. Plaintiffs further allege that Takeda Pharmaceuticals failed to provide adequate warnings to doctors and patients regarding the drug’s association with an increased risk of bladder cancer. The first trial in the federal Actos litigation is scheduled to begin on January 27, 2014.

While trials have yet to start in the federal Actos litigation, one has already concluded in California Superior Court. While the jury hearing the Actos lawsuit awarded $6.5 million to a plaintiff who was diagnosed with bladder cancer after taking the drug for four years, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Actos users treated with the medication for an extended period of time may be entitled to compensation if they were diagnosed with bladder cancer. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

*, FDA, June 15, 2011
**, Bloomberg, March 5, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Actos Lawsuit News: More Than a Dozen Lawsuits Filed in West Virginia, Rottenstein Law Group LLP Reports
2. Actos Bladder Cancer Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Actos Litigation
3. Actos Diabetes Medication Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
4. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Actos Bladder Cancer Litigation
5. Texas Man Suffering from Bladder Cancer Because of Actos Use, Alleges Lawsuit Filed by Parker Waichman LLP
6. Actos Bladder Cancer Lawsuit News: Bernstein Liebhard LLP Comments on India Regulatory Agency Decision to Ban Actos
7. Actos Caused Bladder Cancer and Wrongful Death of New York Woman, Alleges Lawsuit Filed by Parker Waichman LLP
8. Florida Man Develops Bladder Cancer as Result of Taking Actos, Alleges Lawsuit Filed by Parker Waichman LLP
9. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Recent Status Conference in Federal Actos Bladder Cancer Litigation
10. Actos Lawsuit News: Plaintiff Claims Actos Causes Bladder Cancer, Rottenstein Law Group LLP Reports
11. Lawsuit Alleging Actos Caused Arizona Man’s Bladder Cancer Filed by Parker Waichman LLP
Post Your Comments:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, MTI-GlobalStem, a provider of optimized ... difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing ... is a complete system for culturing and transfecting human pluripotent stem cells ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: